Previous Article | Next Article 
Journal of Virology, August 1999, p. 6526-6532, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Nonproductive Human Immunodeficiency Virus Type 1 Infection in Nucleoside-Treated G0 Lymphocytes
Yael D.
Korin1,2 and
Jerome A.
Zack2,3,*
Department of Pathology and Laboratory
Medicine,1 AIDS
Institute,2 and Division of
Hematology-Oncology, Department of Medicine, and Department of
Microbiology and Molecular Genetics, School of
Medicine,3 University of California, Los
Angeles, Los Angeles, California
Received 19 January 1999/Accepted 26 April 1999
 |
ABSTRACT |
Productive infection by human immunodeficiency virus type 1 (HIV-1)
requires the activation of target cells. Infection of quiescent
peripheral CD4 lymphocytes by HIV-1 results in incomplete, labile,
reverse transcripts. We have previously identified G1b as
the cell cycle stage required for the optimal completion of the reverse
transcription process in T lymphocytes. However, the mechanism(s)
involved in the blockage of reverse transcription remains undefined. In
this study we investigated whether nucleotide levels influence viral
reverse transcription in G0 cells. For this purpose the
role of the enzyme ribonucleotide reductase was bypassed, by adding
exogenous deoxyribonucleosides to highly purified T cells in the
G0 or the G1a phase of the cell cycle. Our data showed a significant increase in the efficiency of the reverse transcription process following the addition of the
deoxyribonucleosides. To define the stability and functionality of
these full reverse transcripts, we used an HIV-1 reporter virus that
expresses the murine heat-stable antigen on the surfaces of infected
cells. Following activation of infected quiescent cells treated with exogenous nucleosides, no increased rescue of productive infection was
seen. Thus, in addition to failure to complete reverse transcription, there was an additional nonreversible blockage of productive infection in quiescent T cells. These experiments have important relevance in the
gene therapy arena, in terms of improving the ability of lentivirus
vectors to enter metabolically inactive cells, such as hematopoietic
stem cells.
 |
INTRODUCTION |
Retroviral replication is greatly
influenced by the metabolic and activation states of the target cell at
the time of infection (1, 19, 20, 24-27). Our previous
studies have established that, in contrast to stimulated lymphocytes,
quiescent CD4+ T cells allow entry of human
immunodeficiency virus (HIV) but fail to allow completion of viral
reverse transcription (26, 27). In addition, we have
recently studied the extent of the T-cell activation that is required
for optimal completion of the HIV-1 reverse transcription process. We
found that in highly purified quiescent T cells, activation through
both the T-cell receptor (TCR)-CD3 complex and the costimulatory
molecule CD28 are needed to allow efficient reverse transcription and
productive infection to occur (9). When quiescent T cells,
free of contaminating antigen-presenting cells, are stimulated through
the TCR alone, they progress only to the G1a phase of the
cell cycle and are not permissive for full reverse transcription.
Furthermore, although cellular division is not needed for reverse
transcription to occur (12, 20, 25), we have shown that
progression past the G1a phase of the cell cycle is
required for the completion of the reverse transcription process.
The mechanisms involved in the blockage of reverse transcription in
quiescent cells and cells arrested at the G1a phase of the
cell cycle remain unidentified. Some potential mechanisms for this
arrest may be a decrease in the function of the enzyme reverse
transcriptase, as well as the presence of cellular inhibitors in
quiescent cells or reverse transcription potentiators in activated cells. It has been suggested by others that low levels of
deoxynucleoside triphosphates (dNTPs) may contribute to this phenomenon
(5, 13, 15, 16). Previous studies involving productive
infection of nondividing, cultured mononuclear phagocytes have shown
that full-length viral DNA accumulated with a slow kinetics, which could be accelerated by addition of exogenous nucleotide precursors, although not to the rate seen in activated T lymphocytes (8, 16). Most circulating peripheral T lymphocytes and many in
lymphoid tissues are in a G0 resting state. Diverse events,
including exposure to growth factors and antigen-mediated activation
are involved in the stimulation of these cells and may result in
different states of cellular activation and cell cycle progression. The intracellular concentration of deoxynucleotides is greatly effected by the differentiation and activation states of the cells (2, 14,
18). The activities of a number of enzymes involved in purine and
pyrimidine metabolism, as well as the enzyme ribonucleotide reductase,
which reduces ribonucleotides to deoxyribonucleotides, vary with the
phase of the cell cycle (3, 22). Thus, there are very low
intracellular concentrations of dNTP pools in resting T lymphocytes and
a significant increase in these concentrations occurs following
activation and progression into the cell cycle (2, 14, 18).
Thus, as others have suggested, it seems likely that the low levels of
dNTP pools in G0 cells contribute to the premature
termination of the reverse transcription process. Indeed, it was
demonstrated by Goulaouic et al. (7) that the addition of
high concentrations of exogenous nucleosides to nonproliferating murine
fibroblasts newly infected with Moloney murine leukemia virus allowed
the completion of the reverse transcription process, without initiating
cell cycle progression.
In this study we investigated whether intracellular nucleotide levels
influence HIV-1 reverse transcription in G0- and
G1a-arrested lymphocytes. Cells in these phases of the cell
cycle rely mostly on the salvage of exogenous deoxynucleosides rather
than on the reduction of de novo-synthesized ribonucleotides
(2). In our system the role of the enzyme ribonucleotide
reductase was bypassed, by exogenously adding all four
deoxyribonucleosides to highly purified T cells in the G0
or the G1a phase of the cell cycle. PCR analysis of DNA
extracts showed a significant increase in the efficiency of the reverse
transcription process with the addition of deoxyribonucleosides prior
to infection with HIV-1. This treatment, however, did not fully restore
the levels of complete reverse transcripts to those seen in cells
costimulated through the CD3 and CD28 activation pathways. To define
the stability and functionality of these full reverse transcripts, we
have used HIV-1 reporter viruses that express the murine heat-stable
antigen (HSA) on the surfaces of infected cells (9).
Following anti-CD3 and anti-CD28 costimulation of infected quiescent
cells treated with exogenous nucleosides, no increased rescue of
productive infection was seen in comparison to the level of rescue seen
in cells not treated with nucleosides. Thus, there is an additional
nonreversible blockage of productive infection of newly activated T cells.
 |
MATERIALS AND METHODS |
Cells and conditions.
Peripheral blood was obtained from
healthy HIV-seronegative blood donors, and peripheral blood lymphocytes
(PBLs) were separated over a Ficoll-Hypaque gradient. Nonadherent (NA)
cells were obtained after macrophages were depleted by adherence to
plastic for 3 h. The highly purified DR
population
was enriched by removal of HLA-DR+ cells as previously
described (11). In addition, PBLs were enriched for
CD4+ cells, to at least 90% purity, by depletion of the
CD8+ cells by a panning technique as previously described
(11). Purified cells were cultured in RPMI 1640 supplemented
with 10% human AB serum, 100 U of penicillin per ml, 100 mg of
streptomycin per ml, and 2 mM glutamine. Cells were stimulated with 1 µg of OKT3 (anti-CD3) monoclonal antibody (MAb) (Ortho Diagnostics, Inc., Raritan, N.J.) per ml immobilized on goat anti-mouse antibody (Fisher)-coated plates alone to mimic TCR stimulation or costimulated with the simultaneous addition of soluble anti-CD28 antibody
(Pharmingen, San Diego, Calif.) at a concentration of 0.1 µg/ml. Some
of the quiescent cells were treated with either a 3.5 mM concentration of the cell cycle inhibitor n-butyrate or with a 5 µM
concentration of the ribonucleotide reductase inhibitor hydroxyurea
(HU) (Sigma, St. Louis, Mo.) for 2 h prior to their costimulation.
To assess the effects of exogenous nucleosides, unstimulated
DR
cells were cultured in the presence or absence of 10 to 50 µM concentrations of each of the nucleosides: 2'-deoxycytidine,
2'-deoxyadenosine, 2'-deoxyguanosine, and 2'-deoxythymidine (Sigma) for
2 h prior to infection with HIV-1. To prevent virus spread and
achieve a single-cycle infection, some of the cells were treated with a 100 nM concentration of a protease inhibitor (PI) (Indinavir; Merck,
Rahway, N.J.) following infection.
Viruses and infections.
Stocks of the HIV-1 molecular clone
NL4-3 and the NL4-3-based reporter construct NL-r-HSAS (9)
were obtained from 24-h harvests of supernatants from CEM cells
electroporated with full-length infectious cloned viral DNA. The
reporter virus construct used in this study was obtained by cloning the
cell surface murine HSA into the vpr region of
HIV-1NL4-3 (9). These supernatants generally
contained 2 to 2.5 mg of viral p24 per ml as assessed by enzyme-linked
immunosorbent assay. Based on results of limiting-dilution assays, when
1 ml of virus was used to infect 106 cells, the
multiplicity of infection was approximately 0.2. To reduce the amount
of contamination with viral DNA derived from cells lysed during
culture, supernatants were filtered and treated with 2 µg of DNase
(Worthington, Lakewood, N.J.) per ml for 30 min at room temperature in
the presence of 0.01 M MgCl2. Infection was accomplished by
incubating cells for 1 to 2 h with virus in the presence of
Polybrene (10 µg/ml). Cells were washed with medium three times to
remove residual free virus and recultured under the appropriate
conditions. Heat-inactivated virus controls were prepared by incubating
the virus for 30 min at 60°C. In some experiments whose results are
not shown, a reporter virus containing the murine HSA cDNA inserted
into the nef gene was used similarly, to rule out effects
due to loss of vpr function.
Flow cytometry for surface markers.
To assess the purity of
the cell populations, 5 × 105 cells were costained
with MAbs (Becton Dickinson, Mountain View, Calif.) against HLA-DR
(major histocompatibility complex class II), CD25 (interleukin 2R),
CD19 (B-cell marker), and CD14 (macrophage marker) cell surface markers
as previously described (11) (data not shown). To determine
viral expression in quiescent and activated cells, cells cultured under
different conditions were costained with MAbs to CD4 (Becton Dickinson)
and murine HSA (Pharmingen). These antibodies were directly conjugated
to phycoerythrin (CD4) and fluorescein isothiocyanate (murine HSA).
Under each of the conditions and at each time point, mouse
immunoglobulin G1 (fluorescein isothiocyanate- and
phycoerythrin-conjugated immunoglobulin G1) were used as antibody
isotype controls. Cells were then fixed in 2% paraformaldehyde. Five
thousand to 10,000 events were acquired on a FACStarplus
flow cytometer (Becton Dickinson). Live cells were gated by using forward-versus-side-scatter dot plots. Data were analyzed by using the CellQuest program (Becton Dickinson).
Cell cycle analysis.
Cells (5 × 105) under
each set of conditions were stained for DNA and RNA content with
7-amino-actinomycin D and pyronin Y, respectively, as previously
described (23) with some modifications. Briefly, cells were
suspended in a buffer containing 0.03% saponin (Sigma). Fifty
microliters of 400 µM 7-amino-actinomycin D (Calbiochem, La Jolla,
Calif.) was added at a final concentration of 20 µM. Cells were
incubated at room temperature for 30 min and cooled on ice for at least
5 min, and 3 µl of 1.7 mM pyronin Y (Polysciences, Warrington, Pa.)
was added to achieve a final concentration of 5 µM, after which the
cells were incubated for an additional 10 min on ice and analyzed. Data
were accumulated on a FACStarplus flow cytometer and
analyzed with the CellQuest program.
Quantitative PCR.
Cells to be subjected to quantitative PCR
were harvested and washed, and DNAs were extracted as previously
described (26). Cells were washed in phosphate-buffered
saline, lysed in urea lysis buffer (4.7 M urea, 1.3% [wt/vol] sodium
dodecyl sulfate, 0.23 M NaCl, 0.67 mM EDTA [pH 8.0], 6.7 mM Tris-HCl
[pH 8.0]), and subjected to phenol-chloroform extraction and ethanol
precipitation. Total nucleic acids resulting from this extraction
procedure were used for PCR amplification. Quantitative PCR was
performed with primers specific for HIV-1 sequences as previously
described (26). The primer pairs M667 and AA55 (R and U5)
and M667 and M661 (long terminal repeat [LTR] and gag)
were used to detect initiation and completion of the HIV-1 reverse
transcription process, respectively. Primers specific for the human
-globin gene were used to determine input of cellular DNA. One
primer from each pair was end labeled with 32P. Following
25 cycles of PCR, samples were resolved on a 6% polyacrylamide gel and
quantitation was performed by value comparison to a standard curve of
known amounts of HIV-1 DNA or cellular DNA from uninfected human PBLs
with an Ambis (San Diego, Calif.) radioanalytic imager.
Statistical analysis.
Rates of reverse transcription in
nucleoside-treated and untreated cells were compared by paired-sample
t tests.
 |
RESULTS |
Effect of exogenous nucleosides on HIV reverse transcription.
We studied the effect of nucleoside addition on the efficiency of the
HIV-1 reverse transcription process in highly purified, CD4+ T cells arrested in the G0 or
G1a stage of the cell cycle. Unstimulated T cells are in
the G0 state prior to progressing into the cell cycle. In
contrast, DR
T cells partially activated with anti-CD3
antibodies alone or NA cells costimulated with anti-CD3 and anti-CD28
antibodies in the presence of the cell cycle inhibitor
n-butyrate are arrested at the G1a phase of the
cell cycle (11). Since the intracellular dNTP concentration
in cells at these phases of the cell cycle is very low and is
controlled by the salvaging of extracellular deoxynucleosides, cells
were cultured in the presence or absence of a 10 µM concentration of
all four deoxynucleosides 2 h prior to, as well as immediately
following, infection with the CXCR4-tropic HIV-1NL4-3 viral
strain. To assess the efficiency of the reverse transcription process
under each set of conditions, we employed quantitative PCR, using the
R-U5 and LTR-gag oligonucleotide primer pairs to detect the
first region of the viral genome synthesized and a region present only
in essentially completed reverse transcripts, respectively. In Fig.
1, NA cell populations were used for
experiments in which cells were treated with the drugs
n-butyrate and HU, as well as for control experiments for
the different activation pathways. Figure 1A shows that following
pretreatment with exogenous nucleosides, there was a substantial
increase in the amount of full-length reverse transcripts in either the
NA or DR
cell populations, arrested in the G0
or G1a phase of the cell cycle. A similar increase occurred
in cells treated prior to costimulation with HU, a ribonucleotide
reductase inhibitor, indicating that the salvage of deoxynucleosides
can override the function of the enzyme ribonucleotide reductase. These
results implicate the levels of nucleotide pools in the efficiency of
the reverse transcription process.


View larger version (78K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Effect of exogenous nucleosides on HIV reverse
transcription. Cells treated as indicated were infected with NL4-3 in
the presence or absence of 10 µM of deoxynucleosides (nuc) per ml.
US, unstimulated cells; CD3, cells stimulated with CD3 alone;
costimulation, cells stimulated with CD3 and CD28; n-butyrate,
costimulated cells treated with n-butyrate prior to
costimulation; HU, costimulated cells treated with HU prior to
costimulation; HI, cells infected with a heat-inactivated virus, as a
negative control for reverse transcription; RT, reverse transcripts. At
17 h postinfection, DNA was harvested and subjected to
quantitative PCR with the primer pairs for the R and U5 regions and the
LTR and gag regions to detect initiation and completion of
the HIV-1 reverse transcription process. Quantitative standards (Stds.)
for 10 to 5,000 copies of viral DNA amplified in parallel are shown on
the right. (B) Statistical analysis to assess the significance of the
nucleoside-induced rescue of the reverse transcription process. The
data are compiled from seven experiments to assess the effect of
nucleoside addition on amounts of complete reverse transcripts in
infected cells arrested in the G0 (US [for unstimulated])
or G1a ( CD3 and n-but [for n-butyrate])
phase of the cell cycle, compared to that on fully activated cells
( CD3+ CD28). *p, P values for the significance of the
level of reverse transcripts (RT) recovered compared to the level
recovered in cells without nucleoside addition; **p, P
values for the significance of the level of reverse transcripts not
recovered in nucleotide (NT)-treated cells compared to the level not
recovered in the costimulated control cells.
|
|
We next assessed the extent of the rescue of the nucleoside-induced
reverse transcription process in cells arrested in the G0
or G1a phase of the cell cycle. Data were collected from
multiple experiments to analyze the effect of nucleoside addition on
amounts of complete reverse transcripts. The reverse transcription in G0- or G1a-arrested cells was compared to that
in fully activated cells costimulated with anti-CD3 and anti-CD28
antibodies. Statistical analysis of the results, summarized in Fig. 1B,
indicated a significantly increased efficiency of the reverse
transcription process in cells treated with nucleosides prior to and
immediately following infection. However, the increased levels of
reverse transcripts were also significantly lower than levels seen in
cells costimulated prior to infection. Similar results were seen
following treatment of cells with either 10 or 50 µM nucleosides.
Thus, while nucleoside addition increases the efficiency of reverse
transcription, it does not fully reconstitute the potential levels seen
for reverse transcription in activated cells.
Effect of exogenous nucleosides on the cell cycle.
We next
determined whether the addition of exogenous nucleosides to the culture
medium alters the state of activation and cell cycle progression of
quiescent or activated cells. Noninfected, unstimulated cells and cells
costimulated with anti CD3 and CD28 antibodies were cultured in the
absence or presence of increasing concentrations of exogenous
nucleosides for 2 days. Cell cycle progression under all conditions was
determined daily by a flow-cytometric technique that allows DNA and RNA
quantitation, as described elsewhere (11) and in Materials
and Methods. As seen in Fig. 2, there is
little change in the state of the cell cycle of the unstimulated (upper
panels) or costimulated (lower panels) cells on day 2 following culture
with up to 50 µM exogenous nucleosides. However, the addition of 100 µM nucleosides 2 h prior to infection and again
immediately thereafter prevented the progression of
costimulated cells from the G1b to the S phase of the
cell cycle (lower panels). Thus, high concentrations of
exogenously added nucleosides can be inhibitory to proliferating cells.
As such, subsequent studies were performed with 10 µM nucleosides.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of exogenous nucleosides on cell cycle. Cell
cycle analysis of unstimulated (upper panels) and costimulated (lower
panels) cells cultured in the absence or presence of increasing
concentrations of exogenous nucleosides (nuc) for 2 days. The different
phases of the cell cycle are shown in the lower left panel. Percentages
of cells at the different phases of the cell cycle are indicated inside
the respective quadrants for each of the conditions. 7AAD,
7-amino-actinomycin D. PY, pyronin Y.
|
|
The stability and functionality of the recovered reverse
transcripts in G0 cells.
Our previous studies have
shown an inefficient viral rescue following mitogenic stimulation of
quiescent cells infected with replication-defective
HIV-1JRCSF pseudotyped with a murine amphotropic envelope
glycoprotein (27). To define the stability and functionality of the recovered reverse transcripts following the addition of exogenous nucleosides to G0 cells, we used NL-r-HSAS, a
replication-competent HIV-1 reporter virus, that expresses the murine
HSA on the surfaces of infected cells (9). The HSA gene is
inserted in place of the HIV-1NL4-3 vpr gene,
and expression can be detected on infected cells by flow cytometry,
thus identifying productive infection on a per cell basis. Infected
cells were treated with the PI Indinavir following exposure to virus,
in order to prevent viral replication and obtain a single-cycle
infection. To examine the efficiency of the PI treatment, prestimulated
cells were infected with NL-r-HSAS and 17 h postinfection 100 nM
PI was added. Following infection, cells were stained and analyzed for
HSA expression. As shown in Fig. 3, 2
days postinfection, HSA+ cells were detected in about the
same amounts in both PI-treated and nontreated cells. However, at the
later time points, viral spread was clearly noticeable in cells not
treated with PI, as indicated by the increasing numbers of
HSA+ cells. In cells treated with PI, the initial number of
HSA+ cells remained constant for a period before declining.
This loss of HSA+ cells at the later time point is most
likely due to death of infected cells. Thus, viral expression is not
altered by PI treatment; however, spread to new cells is inhibited.
This method provides a single-cycle replication assay to assess levels
of productively infected cells.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Postinfection addition of PI prevents HIV replication.
(Right panels) PI (100 nM) was added 17 h following infection of
costimulated cells with the reporter virus NL-r-HSAS. (Left panels)
Cells that received no drug. At the indicated time points, cells were
collected and stained for the virus-encoded HSA surface marker.
Percentages of HSA+ cells are indicated at the M1 gate in
the corresponding histograms. Results with mock-infected cells are
shown in the top panel.
|
|
To determine if the increased levels of reverse transcripts seen
following nucleoside treatment were functional, highly purified CD4+ T cells in the G0 phase of the cell cycle,
as well as previously costimulated cells, were infected with the
NL4-3-based reporter virus NL-r-HSAS. Half of the cells were treated
with 10 µM deoxyribonucleosides 2 h prior to and an additional
10 µM immediately following the infection. Seventeen hours
postinfection, some of the cells were harvested and DNA was extracted
for PCR analysis. The remainder of the unstimulated cells were
costimulated with anti-CD3 and anti-CD28 antibodies in the presence or
absence of 100 nM PI. Figure
4A shows the predicted
increase in efficiency of reverse transcription from 7 to 57%
following the addition of exogenous nucleosides to G0
cells. In addition, precostimulated cells treated with PI exhibited a
similar level of efficiency in reverse transcription, indicating no
effect caused by PI on the reverse transcription process itself. To
determine the effect of nucleoside addition on virus expression
following costimulation, cells were costained for HSA and CD4 surface
markers at subsequent time points. As shown in Fig. 4B, the levels of
productive infection in quiescent cells not treated with exogenous
nucleosides were consistent with the low level of full reverse
transcription seen (Fig. 4A). Interestingly, at all time points tested,
the numbers of HSA+ cells in cultures treated with
exogenous deoxynucleosides were not different from those in cultures
that were not treated. Thus, despite an eightfold increase in levels of
complete reverse transcripts, no increased rescue of productive
infection was seen following activation of nucleoside-treated cells. To
rule out the possibility that infection was affected by the usage of a
vpr-negative virus, we performed all experiments in parallel
with a reporter virus containing a functional vpr gene and
HSA sequences inserted into the nef gene. We obtained
similar results with this reporter; thus, the lack of rescue of
productive infection following activation was not due specifically to
the loss of vpr or nef.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
(A) HIV-1 reverse transcription of cells infected with
NL-r-HSAS following addition of exogenous nucleosides. Unstimulated and
costimulated cells were infected with 3 µg of p24 of NL-r-HSAS per
106 cells in the presence or absence of 10 µM of
deoxynucleosides (nuc) per ml. Seventeen hours later DNA was harvested
and subjected to quantitative PCR with the primer pairs for the R-U5
and LTR-gag regions in the viral DNA and with a primer for
the -globin gene of the genomic DNA. Percentages of initiated
reverse transcripts that completed the reverse transcription process
(% of full RT) as well as percentages of cells in the population that
harbor complete reverse transcription as determined by assessing levels
of LTR and gag per -globin signal (% of infection) are
indicated for each of the conditions. US, unstimulated; CD3+CD28,
costimulated. Quantitative standards (Stds.) are shown on the right for
each primer pair and for the -globin primer. (B) Effect of
nucleoside addition on viral rescue. The quiescent or
nucleoside-treated quiescent cells shown in panel A were costimulated
17 h postinfection in the presence of 100 nM PI. At the indicated
time points cells were collected and stained for the virus-encoded HSA
surface marker. Percentages of HSA+ cells are indicated in
each of the corresponding histograms. The results are representative of
three separate experiments.
|
|
 |
DISCUSSION |
Although full activation of T cells is not necessary for proviral
DNA synthesis, we have previously shown that transition into the
G1b phase of the cell cycle was required to efficiently complete the reverse transcription process (11). In the
present work we studied the potential role of dNTP concentrations in
the HIV-1 reverse transcription block in quiescent cells and cells arrested at the G1a phase of the cell cycle. We have used
our previously described system of highly purified DR
CD4+ enriched primary T-cell cultures. In this system,
resting lymphocytes are in the G0 phase of the cell cycle,
while cells activated with anti-CD3 antibodies alone, or cells treated
with the cell cycle inhibitor n-butyrate prior to
costimulation with anti-CD3 and anti-CD28 antibodies, are arrested in
the G1a phase of the cell cycle (11). Here we
show that the addition of all four deoxyribonucleosides to culture
media of cells in the G0 and G1a phase of the
cell cycle partially alleviated the blockage of complete reverse
transcription without having an effect on the state of the cell cycle.
While the increased efficiency of the reverse transcription was
significant, it was also significantly lower than that seen in fully
activated T lymphocytes costimulated with both anti-CD3 and anti-CD28
antibodies. These results suggest that in addition to dNTP
concentration, some other factor(s) may be needed to fully restore the
levels of complete reverse transcripts in quiescent and partially
activated T cells.
In studies designed to investigate the intracellular nucleotide pool,
Cohen et al. (2) demonstrated a 10- to 40-fold increase in
the dGTP, dCTP, and dTTP concentrations, and a 100-fold increase in
dATP levels in resting T lymphocytes following exogenous addition of
the corresponding deoxynucleosides. In addition, several studies have demonstrated the ability of resting T lymphocytes to phosphorylate exogenously added dideoxynucleoside analogs, which then compete with intracellular dNTPs and consequently inhibit HIV-1 proviral synthesis (4, 6, 17). Thus, while uptake of these
nucleosides is less efficient in quiescent than in activated cells, our
experiments show that these increased levels are sufficient to allow
complete reverse transcription of the HIV genome. It was also
previously shown that the addition of dNTPs to isolated HIV-1 virions
could stimulate intravirion reverse transcription activity,
leading to higher levels of virions carrying incomplete reverse
transcripts (28, 29). In our system CD4+ T cells
rather than cell-free virions were cultured in the presence of all
four deoxynucleosides prior to and following, but not during, infection. Thus, the increase in the level of full reverse transcripts seen in our study is likely the result of higher levels of
intracellular dNTPs rather than higher levels of dNTPs invirions.
We further assessed the stability and functionality of the full reverse
transcripts in these cells. For this purpose, we used an HIV-1 reporter
construct that expresses the murine HSA on the surfaces of infected
cells and treated the cells with PI to prevent spread of infection as a
result of viral replication. We showed that following costimulation of
cells 17 h postinfection, no increased rescue of productive
infection was seen in cells treated with exogenous nucleosides. These
results indicate that either the complete reverse transcripts seen in
cells treated with exogenous nucleosides may be defective or there may
be an additional blockage of productive infection of the newly
activated T cells. The latter possibility is consistent with some of
our previous data (27) showing inefficient rescue of viral
production by stimulation with phytohemagglutinin 15 h
postinfection. Furthermore, our results support those of a previously
published report by Tang et al. (21) that showed no rescue
of viral expression in highly purified quiescent T cells activated
postinfection. Thus, the newly synthesized partial or complete reverse
transcripts may be highly labile in G0 cells prior to
nuclear import and integration. A recent report by Kinoshita
(10) looked at potential involvement of some early events in
T-cell activation in the blockage of the HIV reverse transcription
process. Kinoshita identified the transcription factor NFATc as a host
factor that may be involved in controlling productive infection,
possibly by improving the reverse transcription process in suboptimaly
activated CD4+ cells. Our results are consistent with those
conclusions; however, additional work is needed to further elucidate
the fate of proviral DNA at the different stages of cellular activation.
 |
ACKNOWLEDGMENTS |
We thank Steve Cole for providing the statistical analysis for
Fig. 1B.
This work was supported by NIH grants AI33259 and HL55205, the
University of California
Los Angeles CFAR, and an AMGEN Fellowship from the UCLA AIDS Institute (to Y.D.K.). J.A.Z. is an Elizabeth Glaser
Scientist supported by the Pediatric AIDS Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Hematology-Oncology, Department of Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095-1678. Phone: (310) 794-7765. Fax: (310) 825-6192. E-mail: jzack{at}ucla.edu.
 |
REFERENCES |
| 1.
|
Chen, I. S., and H. M. Temin.
1982.
Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection.
J. Virol.
41:183-191[Abstract/Free Full Text].
|
| 2.
|
Cohen, A.,
J. Barankiewicz,
H. M. Lederman, and E. W. Gelfand.
1983.
Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism.
J. Biol. Chem.
258:12334-12340[Abstract/Free Full Text].
|
| 3.
|
Eriksson, S.,
L. Thelander, and M. Akerman.
1979.
Allosteric regulation of calf thymus ribonucleoside diphosphate reductase.
Biochemistry
18:2948-2952[Medline].
|
| 4.
|
Gao, W. Y.,
R. Agbaria,
J. S. Driscoll, and H. Mitsuya.
1994.
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.
J. Biol. Chem.
269:12633-12638[Abstract/Free Full Text].
|
| 5.
|
Gao, W. Y.,
A. Cara,
R. C. Gallo, and F. Lori.
1993.
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.
Proc. Natl. Acad. Sci. USA
90:8925-8928[Abstract/Free Full Text].
|
| 6.
|
Gao, W. Y.,
T. Shirasaka,
D. G. Johns,
S. Broder, and H. Mitsuya.
1993.
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
J. Clin. Investig.
91:2326-2333.
|
| 7.
|
Goulaouic, H.,
F. Subra,
J. F. Mouscadet,
S. Carteau, and C. Auclair.
1994.
Exogenous nucleosides promote the completion of MoMLV DNA synthesis in G0-arrested Balb c/3T3 fibroblasts.
Virology
200:87-97[Medline].
|
| 8.
|
Heinzinger, N.,
L. Baca-Regen,
M. Stevenson, and H. E. Gendelman.
1995.
Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1.
Virology
206:731-735[Medline].
|
| 9.
|
Jamieson, B. D., and J. A. Zack.
1998.
In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus.
J. Virol.
72:6520-6526[Abstract/Free Full Text].
|
| 10.
|
Kinoshita, S.
1998.
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells.
Cell
95:595-604[Medline].
|
| 11.
|
Korin, Y. D., and J. A. Zack.
1998.
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.
J. Virol.
72:3161-3168[Abstract/Free Full Text].
|
| 12.
|
Li, G.,
M. Simm,
M. J. Potash, and D. J. Volsky.
1993.
Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells.
J. Virol.
67:3969-3977[Abstract/Free Full Text].
|
| 13.
|
Lori, F.,
A. Malykh,
A. Cara,
D. Sun,
J. N. Weinstein,
J. Lisziewicz, and R. C. Gallo.
1994.
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
Science
266:801-805[Abstract/Free Full Text].
|
| 14.
|
Marijnen, Y. M.,
D. de Korte,
W. A. Haverkort,
E. J. den Breejen,
A. H. van Gennip, and D. Roos.
1989.
Studies on the incorporation of precursors into purine and pyrimidine nucleotides via `de novo' and `salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells.
Biochim. Biophys. Acta
1012:148-155[Medline].
|
| 15.
|
Meyerhans, A.,
J. P. Vartanian,
C. Hultgren,
U. Plikat,
A. Karlsson,
L. Wang,
S. Eriksson, and S. Wain-Hobson.
1994.
Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.
J. Virol.
68:535-540[Abstract/Free Full Text].
|
| 16.
|
O'Brien, W. A.,
A. Namazi,
H. Kalhor,
S. H. Mao,
J. A. Zack, and I. S. Chen.
1994.
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.
J. Virol.
68:1258-1263[Abstract/Free Full Text].
|
| 17.
|
Shirasaka, T.,
S. Chokekijchai,
A. Yamada,
G. Gosselin,
J. L. Imbach, and H. Mitsuya.
1995.
Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells.
Antimicrob. Agents Chemother.
39:2555-2559[Abstract].
|
| 18.
|
Spaapen, L. J.,
J. G. Scharenberg,
B. J. Zegers,
G. T. Rijkers,
M. Duran, and S. K. Wadman.
1986.
Intracellular purine and pyrimidine nucleotide pools of human T and B lymphocytes.
Adv. Exp. Med. Biol.
195A:567-573.
|
| 19.
|
Stevenson, M.,
B. Brichacek,
N. Heinzinger,
S. Swindells,
S. Pirruccello,
E. Janoff, and M. Emerman.
1995.
Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden.
Adv. Exp. Med. Biol.
374:33-45[Medline].
|
| 20.
|
Stevenson, M.,
T. L. Stanwick,
M. P. Dempsey, and C. A. Lamonica.
1990.
HIV-1 replication is controlled at the level of T cell activation and proviral integration.
EMBO J.
9:1551-1560[Medline].
|
| 21.
|
Tang, S.,
B. Patterson, and J. A. Levy.
1995.
Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.
J. Virol.
69:5659-5665[Abstract].
|
| 22.
|
Thelander, L., and P. Reichard.
1979.
Reduction of ribonucleotides.
Annu. Rev. Biochem.
48:133-158[Medline].
|
| 23.
|
Toba, K.,
E. F. Winton,
T. Koike, and A. Shibata.
1995.
Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y.
J. Immunol. Methods
182:193-207[Medline].
|
| 24.
|
Varmus, H. E.,
T. Padgett,
S. Heasley,
G. Simon, and J. M. Bishop.
1977.
Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA.
Cell
11:307-319[Medline].
|
| 25.
|
Zack, J. A.
1995.
The role of the cell cycle in HIV-1 infection.
Adv. Exp. Med. Biol.
374:27-31[Medline].
|
| 26.
|
Zack, J. A.,
S. J. Arrigo,
S. R. Weitsman,
A. S. Go,
A. Haislip, and I. S. Chen.
1990.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Cell
61:213-222[Medline].
|
| 27.
|
Zack, J. A.,
A. M. Haislip,
P. Krogstad, and I. S. Chen.
1992.
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
J. Virol.
66:1717-1725[Abstract/Free Full Text].
|
| 28.
|
Zhang, H.,
G. Dornadula, and R. J. Pomerantz.
1996.
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells.
J. Virol.
70:2809-2824[Abstract].
|
| 29.
|
Zhang, H.,
Y. Zhang,
T. P. Spicer,
L. Z. Abbott,
M. Abbott, and B. J. Poiesz.
1993.
Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance.
AIDS Res. Hum. Retroviruses
9:1287-1296[Medline].
|
Journal of Virology, August 1999, p. 6526-6532, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Garcia, M., Yu, X.-F., Griffin, D. E., Moss, W. J.
(2008). Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J. Gen. Virol.
89: 984-993
[Abstract]
[Full Text]
-
King, S. R., Duggal, N. K., Ndongmo, C. B., Pacut, C., Telesnitsky, A.
(2008). Pseudodiploid Genome Organization Aids Full-Length Human Immunodeficiency Virus Type 1 DNA Synthesis. J. Virol.
82: 2376-2384
[Abstract]
[Full Text]
-
Plesa, G., Dai, J., Baytop, C., Riley, J. L., June, C. H., O'Doherty, U.
(2007). Addition of Deoxynucleosides Enhances Human Immunodeficiency Virus Type 1 Integration and 2LTR Formation in Resting CD4+ T Cells. J. Virol.
81: 13938-13942
[Abstract]
[Full Text]
-
Munk, C., Zielonka, J., Constabel, H., Kloke, B.-P., Rengstl, B., Battenberg, M., Bonci, F., Pistello, M., Lochelt, M., Cichutek, K.
(2007). Multiple Restrictions of Human Immunodeficiency Virus Type 1 in Feline Cells. J. Virol.
81: 7048-7060
[Abstract]
[Full Text]
-
Vatakis, D. N., Bristol, G., Wilkinson, T. A., Chow, S. A., Zack, J. A.
(2007). Immediate Activation Fails To Rescue Efficient Human Immunodeficiency Virus Replication in Quiescent CD4+ T Cells. J. Virol.
81: 3574-3582
[Abstract]
[Full Text]
-
Oswald-Richter, K., Torres, V. J., Sundrud, M. S., VanCompernolle, S. E., Cover, T. L., Unutmaz, D.
(2006). Helicobacter pylori VacA Toxin Inhibits Human Immunodeficiency Virus Infection of Primary Human T Cells. J. Virol.
80: 11767-11775
[Abstract]
[Full Text]
-
Chen, B., Nelson, D. M., Sadovsky, Y.
(2006). N-Myc Down-regulated Gene 1 Modulates the Response of Term Human Trophoblasts to Hypoxic Injury. J. Biol. Chem.
281: 2764-2772
[Abstract]
[Full Text]
-
Swiggard, W. J., Baytop, C., Yu, J. J., Dai, J., Li, C., Schretzenmair, R., Theodosopoulos, T., O'Doherty, U.
(2005). Human Immunodeficiency Virus Type 1 Can Establish Latent Infection in Resting CD4+ T Cells in the Absence of Activating Stimuli. J. Virol.
79: 14179-14188
[Abstract]
[Full Text]
-
Monie, D., Simmons, R. P., Nettles, R. E., Kieffer, T. L., Zhou, Y., Zhang, H., Karmon, S., Ingersoll, R., Chadwick, K., Zhang, H., Margolick, J. B., Quinn, T. C., Ray, S. C., Wind-Rotolo, M., Miller, M., Persaud, D., Siliciano, R. F.
(2005). A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients. J. Virol.
79: 5185-5202
[Abstract]
[Full Text]
-
Zhou, Y., Zhang, H., Siliciano, J. D., Siliciano, R. F.
(2005). Kinetics of Human Immunodeficiency Virus Type 1 Decay following Entry into Resting CD4+ T Cells. J. Virol.
79: 2199-2210
[Abstract]
[Full Text]
-
Consiglio, A., Gritti, A., Dolcetta, D., Follenzi, A., Bordignon, C., Gage, F. H., Vescovi, A. L., Naldini, L.
(2004). From the Cover: Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc. Natl. Acad. Sci. USA
101: 14835-14840
[Abstract]
[Full Text]
-
Han, Y., Lassen, K., Monie, D., Sedaghat, A. R., Shimoji, S., Liu, X., Pierson, T. C., Margolick, J. B., Siliciano, R. F., Siliciano, J. D.
(2004). Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes. J. Virol.
78: 6122-6133
[Abstract]
[Full Text]
-
Triques, K., Stevenson, M.
(2004). Characterization of Restrictions to Human Immunodeficiency Virus Type 1 Infection of Monocytes. J. Virol.
78: 5523-5527
[Abstract]
[Full Text]
-
Trobridge, G., Russell, D. W.
(2004). Cell Cycle Requirements for Transduction by Foamy Virus Vectors Compared to Those of Oncovirus and Lentivirus Vectors. J. Virol.
78: 2327-2335
[Abstract]
[Full Text]
-
Wu, Y., Marsh, J. W.
(2003). Early Transcription from Nonintegrated DNA in Human Immunodeficiency Virus Infection. J. Virol.
77: 10376-10382
[Abstract]
[Full Text]
-
Cavalieri, S., Cazzaniga, S., Geuna, M., Magnani, Z., Bordignon, C., Naldini, L., Bonini, C.
(2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood
102: 497-505
[Abstract]
[Full Text]
-
O'Doherty, U., Swiggard, W. J., Jeyakumar, D., McGain, D., Malim, M. H.
(2002). A Sensitive, Quantitative Assay for Human Immunodeficiency Virus Type 1 Integration. J. Virol.
76: 10942-10950
[Abstract]
[Full Text]
-
Ducrey-Rundquist, O., Guyader, M., Trono, D.
(2002). Modalities of Interleukin-7-Induced Human Immunodeficiency Virus Permissiveness in Quiescent T Lymphocytes. J. Virol.
76: 9103-9111
[Abstract]
[Full Text]
-
Ruff, C. T., Ray, S. C., Kwon, P., Zinn, R., Pendleton, A., Hutton, N., Ashworth, R., Gange, S., Quinn, T. C., Siliciano, R. F., Persaud, D.
(2002). Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure. J. Virol.
76: 9481-9492
[Abstract]
[Full Text]
-
Pierson, T. C., Zhou, Y., Kieffer, T. L., Ruff, C. T., Buck, C., Siliciano, R. F.
(2002). Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection. J. Virol.
76: 8518-8531
[Abstract]
[Full Text]
-
Katz, R. A., Greger, J. G., Darby, K., Boimel, P., Rall, G. F., Skalka, A. M.
(2002). Transduction of Interphase Cells by Avian Sarcoma Virus. J. Virol.
76: 5422-5434
[Abstract]
[Full Text]
-
Maurice, M., Verhoeyen, E., Salmon, P., Trono, D., Russell, S. J., Cosset, F.-L.
(2002). Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood
99: 2342-2350
[Abstract]
[Full Text]
-
Kuhn, U., Terunuma, A., Pfutzner, W., Foster, R. A., Vogel, J. C.
(2002). In Vivo Assessment of Gene Delivery to Keratinocytes by Lentiviral Vectors. J. Virol.
76: 1496-1504
[Abstract]
[Full Text]
-
Bell, P., Montaner, L. J., Maul, G. G.
(2001). Accumulation and Intranuclear Distribution of Unintegrated Human Immunodeficiency Virus Type 1 DNA. J. Virol.
75: 7683-7691
[Abstract]
[Full Text]
-
McKnight, A., Griffiths, D. J., Dittmar, M., Clapham, P., Thomas, E.
(2001). Characterization of a Late Entry Event in the Replication Cycle of Human Immunodeficiency Virus Type 2. J. Virol.
75: 6914-6922
[Abstract]
[Full Text]
-
Neil, S., Martin, F., Ikeda, Y., Collins, M.
(2001). Postentry Restriction to Human Immunodeficiency Virus-Based Vector Transduction in Human Monocytes. J. Virol.
75: 5448-5456
[Abstract]
[Full Text]
-
Mikkola, H., Woods, N.-B., Sjögren, M., Helgadottir, H., Hamaguchi, I., Jacobsen, S.-E., Trono, D., Karlsson, S.
(2000). Lentivirus Gene Transfer in Murine Hematopoietic Progenitor Cells Is Compromised by a Delay in Proviral Integration and Results in Transduction Mosaicism and Heterogeneous Gene Expression in Progeny Cells. J. Virol.
74: 11911-11918
[Abstract]
[Full Text]
-
Clark, E., Santiago, F., Deng, L., Chong, S. y., de la Fuente, C., Wang, L., Fu, P., Stein, D., Denny, T., Lanka, V., Mozafari, F., Okamoto, T., Kashanchi, F.
(2000). Loss of G1/S Checkpoint in Human Immunodeficiency Virus Type 1-Infected Cells Is Associated with a Lack of Cyclin-Dependent Kinase Inhibitor p21/Waf1. J. Virol.
74: 5040-5052
[Abstract]
[Full Text]